Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination

International Journal of Pharmaceutics

Volumn 381, Issue 2, 2009, Pages 97-105

  Heuking, S ^a,b   Iannitelli, A ^a,b,c   Di Stefano, A ^c   Borchard, G ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Parc d'Affaires International   (France)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biopolymer for mucosal vaccination; Carboxymethyl trimethyl chitosan; Toll like receptor 2 agonist; Water soluble chitosan

Indexed keywords

6 O CARBOXYMETHYL N,N,N TRIMETHYL CHITOSAN; CHITOSAN DERIVATIVE; OMEGA AMIDO [NALPHA PALMITOYL OXY [2,3 BIS(PALMITOYL OXY) 2 PROPYL] CYSTEINYL] ALPHA AMINO POLY(ETHYLENE GLYCOL); TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL ANALYSIS; CHEMICAL BOND; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SYNTHESIS; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MUCOSAL IMMUNITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; VACCINATION;

BIOCOMPATIBLE MATERIALS; CHITOSAN; CYSTEINE; DRUG CARRIERS; IMMUNITY, MUCOSAL; LIGANDS; METHYLATION; MOLECULAR STRUCTURE; MUCOUS MEMBRANE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; POLYETHYLENE GLYCOLS; POLYMERS; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TOLL-LIKE RECEPTOR 2; VACCINATION;

EID: 70349295211     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.03.039     Document Type: Article

References (32)

1. Baudner C.B., Morandi M., Giuliani M.M., Verhoef J.C., Junginger H.E., Costantino P., Rappuoli R., and Giudice G.D. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189 (2004) 828-832
2. Baudner C.B., Verhoef J.C., Giuliani M.M., Peppoloni S., Rappuoli R., Giudice G.D., and Junginger H.E. Protectice immune response to group C meningococcal conjugate vaccine after intranasal immunization of mice together with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Targets 13 (2005) 489-498
3. Bivas-Benita M., van Meijgaarden K.E., Franken K.L.M.C., Junginger H.E., Borchard G., Ottenhoff T.H.M., and Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22 (2004) 1609-1615
4. Chen X., and Park H. Chemical characteristics of O-carboxymethyl chitosans related to the preparation conditions. Carbohydr. Polym. 53 (2003) 355-359
5. Chopra S., Mahdi S., Kaur J., Iqbal Z., Talegaonkar S., and Ahmad F.J. Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery. J. Pharm. Pharmacol. 58 (2006) 1021-1032
6. Florea B.I., Thanou M., Junginger H.E., and Borchard G. Enhancement of bronchial octreotide by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J. Control. Release 110 (2006) 353-361
7. Hamman J.H., Schultz C.M., and Kotzé A.F. N-trimethyl chitosan chloride: optimum degree of quaternization for drug absorption enhancement across epithelial cells. Drug. Dev. Ind. Pharm. 29 (2003) 161-172
8. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
9. Jansma C.A., Thanou M., Junginger H.E., and Borchard G. Preparation and characterization of 6-O-carboxymethyl-N-trimethyl chitosan derivative as a potential carrier for targeted polymeric gene and drug delivery. STP Pharma 13 (2003) 63-67
10. Jeong Y.I., Kim D.G., Jang M.K., and Nah J.W. Preparation and spectroscopic characterization of methoxy poly(ethylene glycol)-grafted water-soluble chitosan. Carbohydr. Res. 343 (2008) 282-289
11. Jintapattanakit A., Mao S., Kissel T., and Junyaprasert V.B. Physicochemical properties and biocompatibility of N-trimethyl chitosan: effect of quaternization and dimethylation. Eur. J. Pharm. Biopharm. 70 (2008) 563-571
12. Kleine B., Rapp W., Wiesmüller K.H., Edinger M., Beck W., Metzger J., Ataulakhanov R., Jung G., and Bessler W.G. Lipopeptide-polyoxyethylene conjugates as mitogens and adjuvants. Immunobiology 190 (1994) 53-66
13. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., Balazuc A.M., Mascarell L., and Moingeon P. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy 38 (2008) 1819-1829
14. Mao S., Shuai X., Unger F., Wittmar M., Xie X., and Kissel T. Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers. Biomaterials 26 (2005) 6343-6356
15. Metzger J., Wiesmüller K.H., Schaude R., Bessler W.G., and Jung G. Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations. Int. J. Pept. Protein Res. 37 (1991) 46-57
16. Murata J., Ohya Y., and Ouchi T. Possibility of application of quaternary chitosan having pendant galactose residues as gene delivery tools. Carbohydr. Polym. 29 (1996) 69-74
17. Murata J., Ohya Y., and Ouchi T. Design of quaternary chitosan conjugate having antennary galactose residues as gene delivery tools. Carbohydr. Polym. 32 (1997) 105-109
18. ÓHagan D.T., Singh M., and Ulmer J.B. Microparticle-based technology for vaccines. Methods 40 (2006) 10-19
19. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11 (2005) 63-68
20. Polnok A., Borchard G., Verhoef J.C., Sarisuta N., and Junginger H.E. Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. Eur. J. Pharm. Biopharm. 57 (2004) 77-83
21. Prabaharan M., Reis R.L., and Mano J.F. Carboxymethyl chitosan-graft-phosphatidyl-ethanolamine: amphiphilic matrices for controlled drug delivery. React. Funct. Polym. 67 (2007) 43-52
22. Prabaharan M., and Gong S. Novel thiolated carboxymethyl chitosan-g-β-cyclodextrin as mucoadhesive hydrophobic drug delivery carriers. Carbohydr. Polym. 73 (2008) 117-125
23. Qin C., Li H., Xiao Q., Liu Y., Zhu J., and Du Y. Water-solubility of chitosan and its antimicrobial activity. Carbohydr. Polym. 63 (2006) 367-374
24. Sahni J.K., Copra S., Ahmad F.J., and Khar R.K. Potential prospects of chitosan derivative trimethyl chitosan chloride (TMC) as a polymeric absorption enhancer: synthesis, characterization and applications. J. Pharm. Pharmacol. 60 (2008) 1111-1119
25. Schmitt A., Li L., Giannopoulos K., Greiner J., Reinhardt P., Wiesneth M., and Schmitt M. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 48 (2008) 861-870
26. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., and Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26 (2008) 1626-1637
27. Sieval A.B., Thanou M., Kotzé A.F., Verhoef J.C., Brussee J., and Junginger H.E. Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydr. Polym. 36 (1998) 157-165
28. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14 (2001) 201-207
29. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52 (2001) 139-144
30. Verheul R.J., Amidi M., van der Wal S., van Riet E., Jiskoot W., and Hennink W.E. Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. Biomaterials 29 (2008) 3642-3649
31. Wedlock D.N., Denis M., Painter G.F., Ainge G.D., Vordermeier H.M., Hewinson R.G., and Buddle B.M. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clin. Vaccine Immunol. 15 (2008) 765-772
32. Wetzler L.M. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 21 (2003) 55-60